HC Wainwright Raises Viridian Therapeutics (NASDAQ:VRDN) Price Target to $34.00

Viridian Therapeutics (NASDAQ:VRDN) had its target price upped by research analysts at HC Wainwright from $27.00 to $34.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 51.25% from the company’s previous close.

VRDN has been the topic of a number of other research reports. BTIG Research increased their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. The Goldman Sachs Group increased their target price on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research report on Thursday, September 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

Viridian Therapeutics Trading Up 0.2 %

Shares of Viridian Therapeutics stock opened at $22.48 on Thursday. Viridian Therapeutics has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.44 billion, a PE ratio of -5.22 and a beta of 1.10. The business’s fifty day moving average is $22.35 and its two-hundred day moving average is $16.89. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05.

Insider Buying and Selling at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the business’s stock in a transaction on Friday, September 13th. The shares were bought at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the transaction, the director now directly owns 3,445,813 shares of the company’s stock, valued at $64,608,993.75. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,600,000 shares of the stock in a transaction dated Friday, September 13th. The stock was bought at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the completion of the purchase, the director now directly owns 3,445,813 shares of the company’s stock, valued at approximately $64,608,993.75. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Stephen F. Mahoney bought 21,400 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now directly owns 21,400 shares of the company’s stock, valued at approximately $499,262. The disclosure for this purchase can be found here. Insiders have purchased 1,626,400 shares of company stock valued at $30,616,312 over the last three months. 0.65% of the stock is owned by company insiders.

Institutional Trading of Viridian Therapeutics

Large investors have recently modified their holdings of the business. FMR LLC grew its stake in Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock worth $254,424,000 after purchasing an additional 1,610,130 shares in the last quarter. Novo Holdings A S grew its stake in Viridian Therapeutics by 81.8% in the second quarter. Novo Holdings A S now owns 2,000,000 shares of the company’s stock worth $26,020,000 after purchasing an additional 900,000 shares in the last quarter. Maverick Capital Ltd. grew its stake in Viridian Therapeutics by 22.9% in the second quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock worth $43,036,000 after purchasing an additional 615,531 shares in the last quarter. Candriam S.C.A. grew its stake in Viridian Therapeutics by 167.8% in the second quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after purchasing an additional 469,804 shares in the last quarter. Finally, Great Point Partners LLC grew its stake in Viridian Therapeutics by 50.0% in the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock worth $17,062,000 after purchasing an additional 250,000 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.